Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Novo Nordisk A/SNYSE: NVO

Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026

Accounts receivables outflow grows to DKK 0

Q2 FY2026 accounts receivables was DKK 0, compared with DKK 0 a year earlier. Trailing-twelve-month accounts receivables was DKK 0.

Context

  • Accounts receivables amounted to 0.0% of revenue in FY2025, down 4.9 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near DKK 0 or moves back toward the trailing-twelve-month quarterly average of DKK 0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
DKK 0— QoQ
Last fiscal yearDec 2025
DKK 0+100.0% YoY
LTMJun 2026
DKK 0— YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

DKK · from the cash flow

Latest · FY2025
0 DKK
Year-over-year change
+100.0%

Accounts Receivables vs competitors

How NVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Accounts receivables amounts to 0.0% of revenue for NVO, versus a peer median of 1.4%.
NVO Competitors
Accounts Receivables for NVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMGNAmgen Inc.LTM Jun 2026$1.53B USD-9.4%+53.1%4.0%
JNJJohnson & JohnsonLTM Sep 2026$1.37B USD+3.7%+11.4%1.4%
ABBVAbbVie Inc.LTM Jun 2026$1.28B USD+66.8%+0.8%2.0%
MRKMerck & Co., Inc.LTM Jun 2026$1.09B USD—+19.2%1.6%
SNYSanofiLTM Jun 2026€753.5M EUR—+39.5%1.5%
NVONovo Nordisk A/SLTM Jun 2026DKK 0 DKK——0.0%
LLYEli Lilly and CompanyLTM Jun 2026$0 USD—+185.9%0.0%
AZNAstraZeneca PLCLTM Sep 2026$0 USD——0.0%
PFEPfizer Inc.LTM Jun 2026$0 USD——0.0%
GSKGSK plcLTM Jun 2026£0 GBP——0.0%
Peer median (excluding NVO) —+3.7%+29.3%1.4%

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income47.76B55.53B83.68B100.99B102.43B
Depreciation & Amortization6.03B7.36B9.41B19.11B21.98B
Deferred Income Tax11.32B13.54B20.99B26.2B28.11B
Stock-Based Compensation1.04B1.54B2.15B2.29B0
Change in Working Capital(8.66B)(5.54B)(12.25B)2.59B3.74B
Accounts Receivables(12.91B)(10.82B)(14.21B)(14.31B)0
Inventory(1.09B)(4.77B)(7.42B)(9.04B)0
Accounts Payables3.15B6.72B10.02B3.24B0
Other Working Capital2.19B3.34B(631M)22.7B3.74B
Other Non-Cash Items(2.49B)6.46B4.92B(30.21B)(37.16B)
Operating Cash Flow55B78.89B108.91B120.97B119.1B
Capital Expenditures(7.39B)(14.75B)(38.9B)(51.31B)(90.11B)
Acquisitions (Net)(18.28B)(7.08B)0(82.16B)1B
Purchases of Investments(7.11B)(9.74B)(13.29B)(19.81B)(723M)
Sales of Investments1.17B6.65B8.29B24.39B10.67B
Other Investing Activities4M(2.61B)(13.09B)(4.15B)(29.97B)
Investing Cash Flow(31.61B)(24.92B)(43.89B)(128.9B)(79.16B)
Debt Repayment15.47B(2.41B)(1.47B)73.06B24.74B
Common Stock Issued00000
Common Stock Repurchased(19.45B)(24.09B)(29.92B)(20.18B)(1.39B)
Dividends Paid(21.52B)(25.3B)(31.77B)(44.14B)(51.76B)
Other Financing Activities00000
Financing Cash Flow(25.49B)(51.8B)(63.16B)8.74B(28.41B)
Effect of Forex Changes591M(238M)(119M)455M(727M)
Net Change in Cash(1.51B)1.93B1.74B1.26B10.81B
Free Cash Flow47.62B64.13B70.01B69.66B28.99B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.